Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

S0360000

Selegiline hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

R-(−)-Deprenyl hydrochloride, (R)-(−)-N,α-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride, R(−)-N-α-Dimethyl-N-2-propynyl-benzeneethanamine hydrochloride, Selegiline hydrochloride

Sign Into View Organizational & Contract Pricing

Select a Size

2 EA
$334.00

$334.00


Check Cart for Availability

Request a Bulk Order

Select a Size

Change View
2 EA
$334.00

About This Item

Empirical Formula (Hill Notation):
C13H17N · HCl
CAS Number:
Molecular Weight:
223.74
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

$334.00


Check Cart for Availability

Request a Bulk Order

grade

pharmaceutical primary standard

API family

selegiline

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl[H].C[C@H](Cc1ccccc1)N(C)CC#C

InChI

1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1

InChI key

IYETZZCWLLUHIJ-UTONKHPSSA-N

Gene Information

human ... MAOB(4129)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Selective MAO-B inhibitor; anti-Parkinsonian agent.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

target_organs

Central nervous system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wakako Maruyama et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(1), 83-89 (2012-08-16)
Neuroprotection has been proposed in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, to delay or halt disease progression or reverse neuronal deterioration. The inhibitors of type B monoamine oxidase (MAO), rasagiline and (-)deprenyl, prevent neuronal loss in cellular and
Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
T Keränen et al.
International journal of clinical practice, 66(10), 1014-1014 (2012-09-22)
Chong Li et al.
Biochemistry. Biokhimiia, 77(6), 671-678 (2012-07-24)
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a glycolytic enzyme, plays an important role in glycolysis. It was reported that GAPDH undergoes S-nitrosylation, which facilitated its binding to Siah1 and resulted in nuclear translocation and cell apoptosis. The results of this study show that
Dhaval R Kalaria et al.
International journal of pharmaceutics, 438(1-2), 202-208 (2012-09-08)
The objective was to investigate the anodal iontophoresis of the MAO-B inhibitors rasagiline (RAS) and selegiline (SEL) across porcine and human skin in vitro. Passive delivery of RAS and SEL from aqueous solution was minimal; however, increasing current density from
Giovanni Fabbrini et al.
Clinical neuropharmacology, 35(3), 134-140 (2012-05-18)
Selegiline at the doses used in Parkinson disease is a selective irreversible monoamine oxidase type B inhibitor, which potentiates dopaminergic function in the brain, and is used as monotherapy in early Parkinson disease or in combination with levodopa in more

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service